Anti-PD-1/Anti-TGF-beta Bifunctional Fusion Protein TQB2868 clinical trials
Its developmentBy Sino Biopharmaceutical, step by step4 company-led studies, furthest phase 3: when each phase was reached, its deals, target and what is ahead.How each study uses Anti-PD-1/Anti-TGF-beta Bifunctional Fusion Protein TQB2868 is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the Anti-PD-1/Anti-TGF-beta Bifunctional Fusion Protein TQB2868 studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your alerts, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your alerts. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Studies by the year they started
7 studies that test it; most in 2022 (2)
| Year | Studies |
|---|---|
| 2022 | 2 |
| 2023 | 2 |
| 2024 | 1 |
| 2025 | 1 |
| 2026 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 4 · Other 3
Fudan University (3) · Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd. (2) · Shanghai Chia Tai Tianqing Pharmaceutical Technology Development Co., Ltd. (1) · Chia Tai Tianqing Pharmaceutical Group Co., Ltd. (1)
Often tested with
Tested in the same studies.
Trastuzumab rezetecan (2) · Camrelizumab (2) · Famitinib (2) · Anti-HER2/Topoisomerase I Inhibitor ADC TQB2102 (2) · Anlotinib (1) · Dalpiciclib (1) · Pyrotinib (1) · Adebrelimab (1)
Coming up
From the study records. Dates are the sponsors’ own estimates and often move.
Reaching primary completion within a year · 1
Studies that test Anti-PD-1/Anti-TGF-beta Bifunctional Fusion Protein TQB2868.
- Nov 2026Clinical Study of TQB2868 Injection Combined With Anlotinib Capsule and Chemotherapy in the First-line Treatment of Metastatic Pancreatic NeoplasmsPhase 2 · Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.
Studies
Open first, then newest update. How each study uses Anti-PD-1/Anti-TGF-beta Bifunctional Fusion Protein TQB2868 is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 7
- Cryoablation Combined With Anlotinib Plus TQB2868 in Patients With Advanced Intrahepatic CholangiocarcinomaNot yet recruitingPhase 2Fudan UniversityNCT07846267Written as TQB2868 InjectionHow we know
- Clinical Trial Comparing TQB2868 Injection Combined With Anlotinib Hydrochloride Capsules With Placebo Combined With Chemotherapy as First-line Treatment for Metastatic Pancreatic Ductal Adenocarcinoma (mPDAC)RecruitingPhase 3Shanghai Chia Tai Tianqing Pharmaceutical Technology Development Co., Ltd.NCT07165951Written as TQB2868 InjectionHow we know
- Fudan University Shanghai Cancer Center Breast Cancer Precision Platform Series Study- Neoadjuvant TherapyRecruitingPhase 2Fudan UniversityNCT05582499Written as TQB2868How we know
- FUSCC Refractory TNBC Platform Study (FUTURE2.0)RecruitingPhase 2Fudan UniversityNCT05749588Written as TQB2102 with TQB2868How we know
- Clinical Study of TQB2868 Injection Combined With Anlotinib Capsule and Chemotherapy in the First-line Treatment of Metastatic Pancreatic NeoplasmsRecruitingPhase 2Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.NCT06767813Written as TQB2868 injectionHow we know
- A Trial of TQB2868 Plus Platinum-based Chemotherapy With or Without Bevacizumab in the First-line Treatment of Persistent, Recurrent, or Metastatic Cervical CancerWithdrawnPhase 2Chia Tai Tianqing Pharmaceutical Group Co., Ltd.NCT05998941Written as TQB2868 injectionHow we know
- Clinical Trial of TQB2868 Injection in Subjects With Advanced Malignant TumorsStatus unknownPhase 1Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.NCT05198505Written as TQB2868 InjectionHow we know